IL5 and asthma: The precursors of ASHMI, MSSM-002, inhibit Group 2 cytokines (the inhibition of IL-4, IL-5, IL-13, and GATA-2 and the enhancement of IFN-γ expression) to relieve asthma symptoms [93,94].